Institutional shares held 81.8 Million
42.1K calls
34K puts
Total value of holdings $746M
$383K calls
$310K puts
Market Cap $610M
66,893,000 Shares Out.
Institutional ownership 122.35%
# of Institutions 185


Latest Institutional Activity in KURA

Top Purchases

Q3 2024
Deep Track Capital, LP Shares Held: 1.96M ($17.9M)
Q3 2024
Siren, L.L.C. Shares Held: 1.34M ($12.2M)
Q3 2024
Suvretta Capital Management, LLC Shares Held: 7.65M ($69.8M)
Q3 2024
Millennium Management LLC Shares Held: 845K ($7.71M)
Q3 2024
Walleye Capital LLC Shares Held: 571K ($5.21M)

Top Sells

Q3 2024
Bvf Inc Shares Held: 3.37M ($30.8M)
Q3 2024
Assenagon Asset Management S.A. Shares Held: 1.05M ($9.59M)
Q3 2024
Sofinnova Investments, Inc. Shares Held: 297K ($2.71M)
Q3 2024
State Street Corp Shares Held: 2.67M ($24.3M)
Q3 2024
Paradigm Biocapital Advisors LP Shares Held: 4.33M ($39.5M)

About KURA

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.


Insider Transactions at KURA

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
174K Shares
From 4 Insiders
Grant, award, or other acquisition 82.5K shares
Exercise of conversion of derivative security 91.1K shares
Sell / Disposition
115K Shares
From 6 Insiders
Open market or private sale 112K shares
Bona fide gift 3K shares

Track Institutional and Insider Activities on KURA

Follow Kura Oncology, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells KURA shares.

Notify only if

Insider Trading

Get notified when an Kura Oncology, Inc. insider buys or sells KURA shares.

Notify only if

News

Receive news related to Kura Oncology, Inc.

Track Activities on KURA